Scarica l'app Stockscreener
46.06
2.81%
-1.33
Dopo l'orario di chiusura:
46.89
0.83
+1.80%
Uniqure Nv Borsa (QURE) Ultime notizie
UniQure (NASDAQ: QURE) files Form 144 to sell 30,000 shares via Citigroup - Stock Titan
UniQure (NASDAQ: QURE) insider notice to sell 21,167 shares - Stock Titan
QURE INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announc - The National Law Review
Price to book forward of uniQure N.V. – SWB:UQ1 - TradingView
uniQure N.V. moves ahead with $225 million public offering. Capital raise reshapes the gene therapy - AD HOC NEWS
Enterprise value to EBITDA forward of uniQure N.V. – SWB:UQ1 - TradingView
Enterprise value to revenue forward of uniQure N.V. – SWB:UQ1 - TradingView
Price to sales forward of uniQure N.V. – GETTEX:UQ1 - TradingView
QURE Maintained by HC Wainwright & Co. -- Price Target Raised to $80 - GuruFocus
Why Did QURE Stock Almost Halve Pre-Market Today? - Stocktwits
Bronstein, Gewirtz & Grossman, LLC Is Investigating uniQure N.V. (QURE) And Encourages Stockholders to Connect - The National Law Review
Price to earnings forward of uniQure N.V. – BMV:QURE/N - TradingView
UniQure surges on plans to seek US nod for gene therapy - MSN
uniQure N.V. Actuals & Estimates (BX:UQ1) - TradingView
Form 144 uniQure N.V. For: 26 June By Investing.com - Investing.com South Africa
Form 144 uniQure N.V. For: 26 June - Investing.com UK
uniQure (QURE) CEO Kapusta sells 35K shares after exercising options - Stock Titan
UniQure (QURE) files Rule 144 to sell 22,402 RSU shares; prior 45,000 sold - Stock Titan
Enterprise value to EBIT forward of uniQure N.V. – NASDAQ:QURE - TradingView
uniQure N.V. Actuals & Estimates (FWB:UQ1) - TradingView
QURE Maintained by Mizuho -- Price Target Raised to $68.00 - GuruFocus
Gene Therapy Co. Announces Initial Data for Refractory Epilepsy Treatment Gets Buy Rating - Streetwise Reports
QURE Stock Just Shot Up 8%uniQure’s Much-Talked-About Huntington’s Disease Therapy Gets A UK Boost - Stocktwits
uniQure N.V. Actuals & Estimates (LS:A1XDTV) - TradingView
uniQure (QURE) Is Up 6.1% After Equity Raise And FDA Backing For Accelerated HD FilingHas The Bull Case Changed? - simplywall.st
QURE Jumps 20% – Analysts Upgrade Stock On Huntington’s Disease Therapy Update, Retail Eyes $150 - Stocktwits
uniQure prices upsized $225M public offering of ordinary shares - MSN
Price to sales forward of uniQure N.V. – LSX:A1XDTV - TradingView
uniQure closes $259M public offering at $45.50 per share By Investing.com - Investing.com South Africa
Enterprise value to revenue forward of uniQure N.V. – LSX:A1XDTV - TradingView
UniQure Closes $259 Million Stock Offering - marketscreener.com
uniQure closes $259M public offering at $45.50 per share - Investing.com
uniQure Closes $259 Million Public Offering of Ordinary Shares - Quiver Quantitative
uniQure Announces Closing of Upsized Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares - The Manila Times
UniQure Announces Closing of Upsized Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares - marketscreener.com
uniQure raises $259M as underwriters buy more shares - Stock Titan
Kapusta (QURE) sells 28,716 shares after option exercise on 06/25/2026 - Stock Titan
Price to earnings forward of uniQure N.V. – LSX:A1XDTV - TradingView
Price to book forward of uniQure N.V. – LSX:A1XDTV - TradingView
Enterprise value to EBIT forward of uniQure N.V. – LSX:A1XDTV - TradingView
Huntington's Disease Market Poised for Significant Growth at a CAGR of 14% During the Forecast Period (2026-2036) Amid Advancements in Disease-Modifying Therapies | DelveInsight - PR Newswire UK
Mizuho raises uniQure stock price target to $68 on FDA meeting optimism - Investing.com Nigeria
UniQure N.V. (QURE) Upgraded to Overweight as Huntington’s Disease Program Advances - Yahoo Finance
uniQure (QURE) Reports Early AMT 260 Data With Seizure Reduction In Epilepsy - Sahm
uniQure Prices Upsized $225 Million Public Offering to Advance Gene Therapy Pipeline - Minichart
Mizuho Securities Maintains UniQure NV(QURE.US) With Buy Rating, Raises Target Price to $68 - Moomoo
uniQure Prices $45.50 Stock Offering; Underwriting With Leerink Partners Nets $242.7 Million - TradingView
uniQure (NASDAQ: QURE) prices $225M underwritten share offering - Stock Titan
uniQure (NASDAQ: QURE) raises $211.5M net to fund AMT-130 launch plans - Stock Titan
uniQure (NASDAQ: QURE) files Rule 144 resale notice listing recent insider sales - Stock Titan
UniQure (QURE) Gains Regulatory Support from FDA Under New Leade - GuruFocus
5 Best Healthcare Stocks to Buy According to Wall Street Analysts - Insider Monkey
uniQure N.V. (QURE) Prices $225M Public Offering of Shares - GuruFocus
What’s next in line for FDA reversals after UniQure and Regenxbio - Seeking Alpha
uniQure N.V. (QURE) Stock Dips Following $225M Share Offering Announcement - Blockonomi
UniQure Prices $225 Million Ordinary Stock Offering - Moomoo
1.28%
1.90%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):